Anti-5T4 Recombinant Immunotoxin Naptumomab estafenatox (5T4(Fab)V18-SEA/E-120) (CAT#: BioBet-IT002Z) Datasheet

Target
5T4
IT Type
Antibody-based IT
Description
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer, such as non-small cell lung cancer and renal cell carcinoma. ABR-217620, a recombinant fusion protein consisting of an antigen-binding fragment of a monoclonal antibody that binds to tumor-associated meconium trophoblast glycoprotein antigen 5T4, which is attached to a mutant form of the Staphylococcus entertoxins A and E (SEA/E-120) superantigens, with immunomodulatory and anti-tumor activity. The Fab part of Naptumomab estafenatox binds to 5T4, which is an antigen expressed by various tumor cells. In turn, superantigens bind to major histocompatibility complex class II molecules and T cell receptor β chains, resulting in massive activation of T lymphocytes and inducing effective T cell mediated tumor cell killing.
Indication
Non-small cell lung carcinoma
Renal cell carcinoma
Classification
Immuntoxin; biobetter
Construction
5T4(Fab)V18-SEA/E-120
CAS number
676258-98-3
UNII
93T929W6LC
Synonyms
ABR-217620); ANYARA (Nap)

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TPBG
Full Name
trophoblast glycoprotein
Background
This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. The encoded protein is an oncofetal antigen that is specific to trophoblast cells. In adults this protein is highly expressed in many tumor cells and is associated with poor clinical outcome in numerous cancers. Alternate splicing in the 5' UTR results in multiple transcript variants that encode the same protein.
Alternative Names
5T4; M6P1; 5T4AG; WAIF1
Antibody Name
Naptumomab
Antibody Clone
5T4
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Type
Fab
Host
Mouse
Species Reactivity
Human
Antibody Description
Naptumomab activates T lymphocytes and targets them to the 5T4-expressing tumors, resulting in massive effector lymphocyte infiltration into the tumor and tumor cell killing.
Antibody Indication
Non-small cell lung carcinoma
Renal cell carcinoma
Toxic Moiety
SEA/E-120
Organism
Staphylococcal enterotoxin A
Toxic MOA
Staphylococcal superantigens are secreted by pathogens and stimulate large-scale MHC II-T cell receptor-mediated polyclonal T cell activation, resulting in the release of large amounts of cytotoxic and pro-inflammatory cytokines, and effectively kill T cell-mediated Tumor cells.

Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody and the superantigen Staphylococcus enterotoxin A (SEA / E-120, "estrogen"). Fab binds to antigen 5T4 expressed by various tumor cells, and superantigen induces immune response by activating T lymphocytes.

Non-small cell lung carcinoma
Renal cell carcinoma

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK